<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2810">
  <stage>Registered</stage>
  <submitdate>10/06/2010</submitdate>
  <approvaldate>10/06/2010</approvaldate>
  <nctid>NCT01142011</nctid>
  <trial_identification>
    <studytitle>A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia</studytitle>
    <scientifictitle>A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HGSI Belimumab in WM</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Symptomatic Waldenstroms Macroglobulinaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Belimumab

Experimental: Belimumab - The first cycle of Belimumab is a loading cycle of 3 doses over 28 days (days 1, 15, 29).
After the first cycle, additional cycles of belimumab will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).


Treatment: drugs: Belimumab
The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).
The infusion will be administered over a minimum period of 1 hour.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of Belimumab infusions in symptomatic WM</outcome>
      <timepoint>Patients are assessed every 28 days while on treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction of IgM paraprotein</outcome>
      <timepoint>Serum Immunoglobulins will be tested every 28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction of splenomegaly and/or lymphadenopathy</outcome>
      <timepoint>This will be tested every 28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in anaemia</outcome>
      <timepoint>Patients will be assessed every 28 days while on treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlate the degree of response with Belimumab levels</outcome>
      <timepoint>Pharmacokinetics will be performed on days 1, 15, 56, 168, 364</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  At least 18 years of age.

          -  Diagnosis of WM histologically confirmed on bone marrow biopsy.

          -  Detectable IgM paraprotein &gt;5 g/L

          -  Less than 3 lines of prior therapy for WM

          -  Full blood count within 4 weeks prior to screening shows ANC &gt;1.0 x109/l AND platelet
             count &gt;50 x109/l

          -  Therapy indicated due to development of one or more of the following:

               1. symptomatic anaemia

               2. hyperviscosity symptoms

               3. rapidly rising paraprotein of &gt;25% or &gt;5g/l over 3 months

               4. splenomegaly

               5. bulky lymphadenopathy

               6. B symptoms or paraneoplastic phenomena, which, in the opinion of the investigator
                  are the result of progressive WM.

          -  Life expectancy &gt;12 months

          -  ECOG &lt; 3

          -  Able to provide informed consent

          -  Ability to understand the requirements of the study, provide written informed consent,
             including consent for the use and disclosure of research-related health information,
             and comply with the protocol procedures, including required study visits.

          -  Subjects of child bearing potential must agree to use effective contraception
             throughout the study and for 3 months after the last dose of belimumab</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior therapy with belimumab.

          -  Pregnant or breast feeding

          -  Chemotherapy, immunotherapy or biological therapy within 4 weeks of enrolment.
             Therapeutic plasma exchange can continue- see section 3.1.4.

          -  Creatinine clearance (calculated by Cockcroft-Gault) &lt; 60ml/min

          -  Bilirubin &gt;2x ULN, ALT &gt;2x ULN.

          -  History of an allergic or anaphylactic reaction to parenteral administration of
             contrast agents, human or murine proteins or monoclonal antibodies, a history of
             severe allergic reaction to drugs, food, or insects requiring medical intervention, or
             a history of hypersensitive triad (having all 3 features of allergic rhinitis with
             nasal polyps, asthma, and aspirin sensitivity).

          -  Prior opportunistic infection including tuberculosis or atypical mycobacterial
             infection, multi-dermatome Herpes Zoster or Pneumocystis pneumonia or invasive fungal
             infection (not including oral or vaginal candidiasis or superficial dermatophytes) .

          -  Active infection with hepatitis B, hepatitis C or HIV or historically positive test or
             test positive at screening for HIV antibody, hepatitis B surface antigen, or hepatitis
             C antibody.

          -  History of organ transplant (eg, heart, lung, kidney, liver) or hematopoietic stem
             cell/marrow transplant.

          -  Planned surgical procedure during the treatment period of this study or a history of
             any other medical disease (eg, cardiopulmonary), laboratory abnormality, or condition
             that, in the opinion of the principal investigator, makes the subject unsuitable for
             the study.

          -  Hospitalization for treatment of infection within 60 days of Day 1.

          -  Use of parenteral (IV or IM) antibiotics (antibacterials, antivirals, anti-fungals, or
             anti parasitic agents) within 60 days of Day 1.

          -  Current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or
             dependence within 364 days prior to Day 1.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2013</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>Alfred Health - Melbourne</hospital>
    <postcode>3002 - Melbourne</postcode>
    <postcode>3181 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Cancer Trials Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Human Genome Sciences Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Hypothesis; That inhibition of plasma Blys by the monoclonal antibody Belimumab will reduce
      both the survival of the lymphoplasmacytoid cells of Waldenstrom Macroglobulinaemia (WM), and
      their production of monoclonal IgM, resulting in a reduction of IgM paraprotein.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01142011</trialwebsite>
    <publication>Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001 Jun;44(6):1313-9.
Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA, Dillon SR, Harder B, Gross JA, Ansell SM. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood. 2006 Apr 1;107(7):2882-8. Epub 2005 Nov 22.
Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W; Belimumab Study Group. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109. doi: 10.1186/ar2506. Epub 2008 Sep 11.
Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001 Aug;15(2):289-302.
Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000 Apr 27;404(6781):995-9.
Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J, Baker KP. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci. 2006 Jun;91(2):586-99. Epub 2006 Mar 3.
Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone M, Bladé J. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006 Mar;6(5):380-3.
Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999 Dec 6;190(11):1697-710.
Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008 Aug;58(8):2453-9. doi: 10.1002/art.23678.
Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, Holler N, Qian F, Mullen C, Strauch K, Browning JL, Ambrose C, Tschopp J. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000 Dec 4;192(11):1677-84.
Scapini P, Carletto A, Nardelli B, Calzetti F, Roschke V, Merigo F, Tamassia N, Pieropan S, Biasi D, Sbarbati A, Sozzani S, Bambara L, Cassatella MA. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood. 2005 Jan 15;105(2):830-7. Epub 2004 Sep 9.
Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, Montecucco C, Cassatella MA. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med. 2003 Feb 3;197(3):297-302.
Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001 Sep 14;293(5537):2111-4. Epub 2001 Aug 16.
Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S, Cachero TG, Finke D, Beermann F, Tschopp J. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med. 2001 Dec 3;194(11):1691-7.
Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol. 2000 Jul;1(1):37-41.
Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, McCabe S, Qiu WR, Kornuc M, Xia XZ, Guo J, Stolina M, Boyle WJ, Sarosi I, Hsu H, Senaldi G, Theill LE. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2000 Sep;1(3):252-6.
Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001 Jan 1;166(1):6-10.
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001 Feb 23;104(4):487-501. Review.
Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231-64. Epub 2001 Dec 19. Review.
Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001 Sep 14;293(5537):2108-11. Epub 2001 Aug 16.
Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, Tumas D, Grewal IS, Dixit VM. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol. 2001 Jul;2(7):638-43.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Ritchie</name>
      <address>The Peter MacCallum Cancer Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>David Ritchie Ritchie</name>
      <address />
      <phone>+61396561111</phone>
      <fax />
      <email>david.ritchie@petermac.org</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>